Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Navitoclax. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 known ✓ | Q07817 | 19/20 | 1.00 |
| ▸ | BCL2 known ✓ | P10415 | 16/20 | 1.00 |
| ▸ | BCL2L2 known ✓ | Q92843 | 2/20 | 1.00 |
| ▸ | BAD | Q92934 | 3/20 | 1.00 |
| ▸ | BCL2L11 | O43521 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Navitoclax SCHEMBL30255921 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| Navitoclax SCHEMBL15005512 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| Navitoclax SCHEMBL522847 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| Navitoclax SCHEMBL29363785 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL2022422 | 0.98 | BCL2L1 (0.96) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL2022805 | 0.97 | BCL2L1 (0.94) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19911641 | 0.97 | BCL2L1 (0.94) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL23258372 | 0.96 | BCL2L1 (0.93) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL1955579 | 0.96 | BCL2L1 (0.93) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL1628079 | 0.96 | BCL2L1 (0.93) | BCL2L1BCL2BADBCL2L2BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | NEWAVE PHARMACEUTICAL INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | NEWAVE PHARMACEUTICAL INC. | 2023-09-21 | — | — | US | disclosed |
| US-11747279-B2 | Optical biomodule for detection of diseases at an early onset | MAZED MOHAMMAD A (US) | 2023-09-05 | — | — | US | disclosed |
| US-11747279-B2 | Optical biomodule for detection of diseases at an early onset | MAZED MOHAMMAD A (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230271979-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271979-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2023-08-31 | — | — | US | disclosed |
| US-11680072-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680072-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230119463-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220402941-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-12-22 | — | — | US | disclosed |
| US-11279711-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220003676-A1 | Optical biomodule for detection of diseases at an early onset | MAZED MOHAMMAD A (US) | 2022-01-06 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210171523-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200190109-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200071329-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2020-03-05 | — | — | US | disclosed |
| US-10377755-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190040062-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2019-02-07 | — | — | US | disclosed |
| US-8748108-B2 | Biomarkers for identifying patient classes | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120178632-A1 | BIOMARKERS FOR IDENTIFYING PATIENT CLASSES | ABBVIE INC. | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377755-B2 | BCL-2 inhibitors | BCL2L1, BCL2, BCL2A1 | BCL2L1 1/4885BCL2 2/4885BCL2L2 5/4885 |
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | BCL2, BCL2L1, BCL2L2 | BCL2L1 2/4885BCL2 1/4885BCL2L2 3/4885 |
| US-11680072-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | BCL2, BCL3, BCL2A1 | BCL2L1 5/4885BCL2 1/4885BCL2L2 6/4885 |
| US-20230119463-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | BCL2, BAK1, BCL2A1 | BCL2L1 4/4885BCL2 1/4885BCL2L2 7/4885 |
| US-11279711-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | BCL2, BCL3, BCL2L10 | BCL2L1 8/4885BCL2 1/4885BCL2L2 5/4885 |
| US-20200071329-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | BCL2L1 1/4885BCL2 2/4885BCL2L2 5/4885 |
| US-20230271979-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | BCL2, BCL3, BCL2L10 | BCL2L1 8/4885BCL2 1/4885BCL2L2 5/4885 |
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | BCL2L1 4/4885BCL2 2/4885BCL2L2 5/4885 |
| US-20200190109-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | BCL2, BCL3, BCL2L10 | BCL2L1 8/4885BCL2 1/4885BCL2L2 5/4885 |
| US-20220402941-A1 | BCL-2 INHIBITORS | BCL2, BCL2L11, BCL2L10 | BCL2L1 4/4885BCL2 1/4885BCL2L2 5/4885 |
| US-20210171523-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | BCL2L1 1/4885BCL2 2/4885BCL2L2 5/4885 |
| US-20190040062-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | BCL2L1 1/4885BCL2 2/4885BCL2L2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.